HSBA.L vs. GSK
HSBA.L (HSBC Holdings plc) and GSK (GlaxoSmithKline plc) are both stocks. HSBA.L operates in Banks - Diversified (Financial Services), while GSK operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, HSBA.L returned 18.05%/yr vs 5.34%/yr for GSK. At a 0.26 correlation, their price movements are largely independent.
Performance
HSBA.L vs. GSK - Performance Comparison
Loading charts...
Different Trading Currencies
HSBA.L is traded in GBp, while GSK is traded in USD. To make them comparable, the GSK values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, HSBA.L achieves a 20.63% return, which is significantly higher than GSK's 5.93% return. Over the past 10 years, HSBA.L has outperformed GSK with an annualized return of 18.05%, while GSK has yielded a comparatively lower 5.34% annualized return.
HSBA.L
- 1D
- 0.76%
- 1M
- 4.48%
- YTD
- 20.63%
- 6M
- 33.00%
- 1Y
- 62.97%
- 3Y*
- 40.74%
- 5Y*
- 33.67%
- 10Y*
- 18.05%
GSK
- 1D
- -1.74%
- 1M
- 3.44%
- YTD
- 5.93%
- 6M
- 5.97%
- 1Y
- 29.10%
- 3Y*
- 15.56%
- 5Y*
- 5.86%
- 10Y*
- 5.34%
HSBA.L vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HSBA.L HSBC Holdings plc | 20.63% | 57.77% | 36.43% | 32.14% | 19.91% | 22.90% | -35.99% | -2.41% | -11.05% | 23.54% |
GSK GlaxoSmithKline plc | 5.93% | 40.46% | -3.48% | 4.23% | -25.50% | 27.94% | -20.13% | 24.32% | 20.54% | -11.36% |
Correlation
The correlation between HSBA.L and GSK is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Jul 5, 2007 | 0.26 |
The correlation between HSBA.L and GSK shifts across timeframes, from 0.15 (3 years) to 0.26 (all time), reflecting how their relationship changes across market environments.
Fundamentals
HSBA.L:
£237.12B
GSK:
$103.15B
HSBA.L:
£1.27
GSK:
$2.85
HSBA.L:
10.80
GSK:
17.78
HSBA.L:
0.52
GSK:
1.19
HSBA.L:
1.91
GSK:
3.16
HSBA.L:
1.36
GSK:
4.38
HSBA.L:
£125.68B
GSK:
$32.78B
HSBA.L:
£61.95B
GSK:
$23.87B
HSBA.L:
£31.98B
GSK:
$11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HSBA.L vs. GSK — Risk / Return Rank
HSBA.L
GSK
HSBA.L vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for HSBC Holdings plc (HSBA.L) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| HSBA.L | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.39 | ||
| Sortino ratioReturn per unit of downside risk | +1.40 | ||
| Omega ratioGain probability vs. loss probability | 1.45 | 1.21 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 3.93 | 1.57 | +2.36 |
| Martin ratioReturn relative to average drawdown | 14.65 | 3.78 | +10.87 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| HSBA.L | GSK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.49 | 1.10 | +1.39 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 1.37 | 0.24 | +1.13 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.73 | 0.24 | +0.49 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.22 | 0.27 | -0.05 |
Drawdowns
HSBA.L vs. GSK - Drawdown Comparison
The maximum HSBA.L drawdown since its inception was -66.05%, which is greater than GSK's maximum drawdown of -41.45%. Use the drawdown chart below to compare losses from any high point for HSBA.L and GSK.
Loading charts...
Drawdown Indicators
| HSBA.L | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -66.05% | -41.45% | -24.60% |
Max Drawdown (1Y)Largest decline over 1 year | -15.96% | -18.61% | +2.65% |
Max Drawdown (3Y)Largest decline over 3 years | -21.98% | -25.71% | +3.73% |
Max Drawdown (5Y)Largest decline over 5 years | -21.98% | -41.45% | +19.47% |
Max Drawdown (10Y)Largest decline over 10 years | -59.96% | -41.45% | -18.51% |
Current DrawdownCurrent decline from peak | -2.74% | -14.96% | +12.22% |
Average DrawdownAverage peak-to-trough decline | -18.74% | -12.21% | -6.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.27% | 7.71% | -3.44% |
Volatility
HSBA.L vs. GSK - Volatility Comparison
The current volatility for HSBC Holdings plc (HSBA.L) is 5.97%, while GlaxoSmithKline plc (GSK) has a volatility of 6.74%. This indicates that HSBA.L experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HSBA.L | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.97% | 6.74% | -0.77% |
Volatility (6M)Calculated over the trailing 6-month period | 20.94% | 18.57% | +2.37% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.25% | 26.61% | -1.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.59% | 24.57% | +0.02% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.77% | 22.80% | +1.97% |
Dividends
HSBA.L vs. GSK - Dividend Comparison
HSBA.L's dividend yield for the trailing twelve months is around 4.06%, more than GSK's 3.41% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.41% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
HSBA.L HSBC Holdings plc | 4.06% | 4.28% | 8.28% | 6.80% | 4.11% | 3.54% | 0.00% | 6.79% | 5.83% | 5.18% | 0.00% | 0.00% |
Financials
HSBA.L vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between HSBC Holdings plc and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HSBA.L vs. GSK - Profitability Comparison
HSBA.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, HSBC Holdings plc reported a gross profit of 15.89B and revenue of 31.56B. Therefore, the gross margin over that period was 50.4%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
HSBA.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, HSBC Holdings plc reported an operating income of 9.18B and revenue of 31.56B, resulting in an operating margin of 29.1%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
HSBA.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, HSBC Holdings plc reported a net income of 7.19B and revenue of 31.56B, resulting in a net margin of 22.8%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
HSBA.L and GSK have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for HSBA.L and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer